亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes

        2022-06-08 05:24:56AngelikiBourazanaGrigoriosGiamouzisJohnSkoularigisFilipposTriposkiadisAndrewXanthopoulos
        World Journal of Cardiology 2022年4期

        Angeliki Bourazana,Grigorios Giamouzis,John Skoularigis,Filippos Triposkiadis,Andrew Xanthopoulos

        Angeliki Bourazana,Grigorios Giamouzis,John Skoularigis,Filippos Triposkiadis,Andrew Xanthopoulos,Department of Cardiology,University Hospital of Larissa,Larissa 41110,Greece

        Abstract Diabetes mellitus (DM) is a health condition characterized by glucose dysregulation and affects millions of people worldwide.The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum,commencing from asymptomatic,subclinical structural abnormalities to severely symptomatic biventricular dysfunction with increased mortality risk.Similarly,the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse.DM leads also to cardiac electrical remodeling reacting on various targets.Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinotropic peptide and constitute a safe and effective glucose lowering treatment option in patients with type 2 DM.Despite DPP-4 inhibitors’ efficacy regarding glycemic control,their effect on cardiovascular outcomes (myocardial infarction,stroke,hospitalization for heart failure,hospitalization for unstable angina,hospitalization for coronary revascularization,and cardiovascular death) in diabetic patients has been neutral.The potential correlation between atrial flutter and DPP-4 inhibitors administration needs further investigation.

        Key Words: Dipeptidyl peptidase-4 inhibitors;Diabetes mellitus;Outcomes;Metaanalysis;Heart failure;Atrial flutter

        TO THE EDITOR

        Diabetes mellitus (DM) is a health condition characterized by glucose dysregulation and affects 237.9 million males and 222 million females worldwide[1].It is an established risk factor of cardiovascular disease,atrial and ventricular arrhythmias,as well as sudden cardiac death[2,3].Dipeptidyl peptidase-4 (DPP-4) inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 DM (T2DM).Nevertheless,pooled recent data on the effect of DPP-4 inhibitors on cardiovascular outcomes and major cardiac arrhythmias are lacking.

        We read with great interest the paper by Patouliaset al[4],who attempted to close the abovementioned knowledge gap by performing a meta-analysis of six randomized controlled trials (52520 patients) concerning the impact of dipeptidyl peptidase-4 (DPP-4) inhibitors on “hard” cardiovascular outcomes and major cardiac arrhythmias.The authors concluded that DPP-4 inhibitors,compared to placebo,had no effect on fatal or non-fatal myocardial infarction,fatal and non-fatal stroke,hospitalization for heart failure,hospitalization for unstable angina,hospitalization for coronary revascularization,and cardiovascular death and did not seem to confer any significant risk for major cardiac arrhythmias,with the exception of atrial flutter,which was associated with an increased risk equal to 52% (relative risk = 1.52,95% confidence interval: 1.03-2.24,I2= 0%).

        We agree with the authors’ insight that the presence of DM per se increases the risk of adverse cardiovascular outcomes and arrhythmias and results in cellular destabilization of myocardial tissue altogether.For example,it has been demonstrated that diabetic patients present an increased propensity for developing heart failure[5].Diabetic cardiomyopathy,defined as ventricular dysfunction in the absence of hypertension or coronary artery disease,has been attributed to the deregulated immune response in type-1 DM (T1DM) and to the background of obesity in the majority of T2DM patients.The amplified immune response of T1DM patients to myocardial injury,leads to the expansion of proinflammatory CD4+ T cells specific to myosin and the development of autoantibodies to MYH6 and other cardiac antigens.On the other hand,obesity that predominates over T2DM patients reduces the palliative actions of circulating natriuretic peptides on ventricular stress,pressure overload,and sympathetic activation.In the absence of natriuretic peptides’ favorable actions,left ventricle hypertrophy,fibrosis,and insulin desensitization in skeletal muscles are more frequently observed in obese patients[5].The presentation of heart failure in diabetic cardiomyopathy extends over a wide phenotypic spectrum,commencing from asymptomatic,subclinical structural abnormalities,developing progressively to severely symptomatic biventricular dysfunction with advanced mortality risk.Similarly,the spectrum of systolic dysfunction in diabetic-induced heart failure is diverse,originating in the heterogeneous risk factors that diabetes comes along,such as hypertension,hyperlipidemia,cardiovascular disease,and chronic kidney disease[6].

        Except for the morphological implications on ventricular myocardium that account for the wide spectrum of left ventricular dysfunction,DM leads to cardiac electrical remodeling reacting on various targets.Among the diabetes-induced electrical disturbances,reduced conduction velocity,prolonged repolarization,and increased QT dispersion have been recognized,all predisposing to ventricular arrhythmias[7,8].T1DM and T2DM lead to action potential duration prolongation,which becomes prominent on electrocardiography with a QRS prolongation in some diabetic patients[9].QT duration prolongation subsequently predisposes to early after depolarizations development and an enhanced risk of torsade de pointes[10].The proposed mechanisms are diabetes-exerted alterations in the function of several proteins involved in ion handling.More specifically,DM modifies ion channels responsible for depolarization as well as repolarization and resting phase[11].Therefore,DM affects essentially all phases of action potential and correlates strongly to ventricular arrhythmias emergence.

        The culprit pathophysiological mechanisms for the occurrence of atrial arrhythmias in DM substrate are not yet in depth elucidated.In atrial myocardium,DM favors the phenotypic switch of fibroblasts to myofibroblasts[12].Mighty it is that diabetes induced atrial neuropathy as well as diabetes generated advanced myofibroblast differentiation promote atrial remodeling and lead to atrial cardiomyopathy overall[13].Nonetheless,on epidemiological basis,DM is a strong independent risk factor for atrial fibrillation (AF) and atrial flutter occurrence.

        Several studies have demonstrated that antidiabetic drugs may have differing effects on the risk of new-onset AF[14].Metformin has been associated with anti-atrial arrhythmic benefits[15].A case control study revealed no association between sulfonylurea and incident AF,whereas the use of insulin was associated with increased risk of new-onset AF[16].A recent meta-analysis showed that DPP-4 inhibitor treatment resulted in a non-significant decrease in the risk for AF,whereas both glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) were associated with a significant decrease in the risk for AF,equal to 14% and 19%,respectively[17].Liraglutide (a GLP1-RA) demonstrated favorable effects on electrophysiological changes regarding AF inducibility and conduction velocity decrease[18].

        DPP-4 inhibitors reduce glucagon and blood glucose levels by raising levels of the endogenous hormones glucagon-like-peptide 1 and glucose-dependent insulinotropic peptide,which are called incretins.Subsequently incretins inhibit glucagon release and increase insulin secretion.Despite DPP-4 inhibitors’ indisputable efficacy regarding glycemic control,their effect on cardiovascular outcomes in diabetic patients,as denoted in the aforementioned and previous studies,has been neutral[19,20].Furthermore,the risk of hypoglycemia is admitted to be increased compared to SGLT2-i.SGLT2-i reduce hyperglycemia through inhibition of glucose reabsorption in the renal proximal tubules.Acting on glucose/Na co-transporter they promote natriuresis and display not solely hypoglycemic effects but also reduce major adverse cardiovascular events (cardiovascular and total mortality,fatal or nonfatal myocardial infarction,or stroke) and hospitalization for heart failure and improve outcome in chronic kidney disease in diabetic and non-diabetic patients[21].GLP1-RA are oral hypoglycemic drugs that mimic the effects of the incretin hormone glucagon-like-peptide 1.GLP-RA stimulate insulin release,inhibit glucagon secretion,and slow gastric emptying.Liraglutide,albiglutide,and dualiglutide have all shown significant decreases in adverse cardiovascular events[22].In line with this evidence,the European Society of Cardiology guidelines recommend the administration of SGLT-2i or GLP1-RA as a first option in the presence of high or remarkably high cardiovascular risk or of cardiovascular disease[23].

        The potential correlation between atrial flutter and DPP-4 inhibitors administration is an interesting finding,but since there is no sheer underlying pathophysiologic mechanism to justify it,more evidence is required to establish this thesis as a widely accepted knowledge admissible in clinical practice.The authors speculated that the abovementioned correlation may stem from the inherent higher risk of atrial flutter that patients with DM carry[24].However,it is also well known that DM per se is a risk factor of AF[24],which in the current meta-analysis was not associated with DPP-4 inhibitor use.

        In conclusion,the authors should be congratulated on their attempt to provide state of the art data on the association between DPP-4 inhibitors and cardiovascular outcomes as well as major cardiac arrhythmias.The reported increased risk of atrial flutter in patients receiving DPP-4 inhibitors needs further investigation (Figure 1).

        Figure 1 Newer oral antidiabetic drugs,glucose levels,and cardiovascular risk.

        FOOTNOTES

        Author contributions:Bourazana A and Xanthopoulos A wrote the letter;Giamouzis G,Skoularigis J,and Triposkiadis F revised the letter;All authors made substantial contributions to conception and design of the study,acquisition of data or analysis and interpretation of data,drafted the article or made critical revisions related to important intellectual content of the manuscript,and gave final approval of the version of the article to be published.

        Conflict-of-interest statement:The authors declare no conflict of interest regarding the present work

        Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license,which permits others to distribute,remix,adapt,build upon this work non-commercially,and license their derivative works on different terms,provided the original work is properly cited and the use is noncommercial.See: https://creativecommons.org/Licenses/by-nc/4.0/

        Country/Territory of origin:Greece

        ORCID number:Angeliki Bourazana 0000-0001-8297-4201;Grigorios Giamouzis 0000-0002-7406-5427;John Skoularigis 0000-0001-7159-2478;Filippos Triposkiadis 0000-0001-6433-4016;Andrew Xanthopoulos 0000-0002-9439-3946.

        S-Editor:Ma YJ

        L-Editor:Filipodia

        P-Editor:Ma YJ

        a级福利毛片| 免费看又色又爽又黄的国产软件| 消息称老熟妇乱视频一区二区| 精品一区二区三区在线观看视频| 人妻系列影片无码专区| 免费人成在线观看播放视频| 大陆国产乱人伦| 自慰无码一区二区三区| 日韩亚洲制服丝袜中文字幕| 青青青草视频手机在线| 亚洲乱色视频在线观看| 国产高清女主播在线观看| 在线观看老湿视频福利| 欧美午夜精品一区二区三区电影| 中文字幕久热精品视频免费| av大片网站在线观看| 亚洲av福利院在线观看| 亚洲欧洲∨国产一区二区三区| 国产精品女同一区二区久久| 亚洲精品中文字幕乱码三区99| 国产人妻鲁鲁一区二区| 青青草97国产精品免费观看| 亚洲男人堂色偷偷一区| 国产二区中文字幕在线观看| 色欲av伊人久久大香线蕉影院| 人妻精品无码一区二区三区| 亚洲AV成人无码天堂| 国产情侣亚洲自拍第一页| 国产精品免费_区二区三区观看| 久久国产成人精品国产成人亚洲 | 成人国产在线播放自拍| 日韩精品视频高清在线| 久久久亚洲欧洲日产国码αv| 伊人久久中文大香线蕉综合| 国产精品av网站在线| 国产激情在线观看免费视频| 成人免费直播| 无码专区中文字幕DVD| 亚洲一区二区女优视频| 国产av无码专区亚洲a∨毛片| 69一区二三区好的精华|